Translating Qualitative Fibrinogen Phenotypes into Human Research: A proposed framework for longitudinal cohorts mechanistic studies and clinical inference

This methodological article proposes a staged framework for translating qualitative fibrinogen phenotypes into human research. It asks whether the ongoing generation of a defined molecular state contributes to a specified clinical condition and whether modifying the responsible pathway produces functional or patient-important consequences. The framework integrates prospective longitudinal cohorts, nested mechanistic experiments using human samples, and a conditional transition to human proof-of-concept studies. Clinical eligibility is defined independently of the laboratory phenotype, while repeated measurements distinguish molecular state, functional behavior, exposure, and evidence of continued generation. Particular attention is given to concentration-matched clot-lysis assays, post-translational modification measurements, purification controls, copurified components, and the analytical linkage between newly produced molecular populations and candidate modifications. Time-indexed causal models address reverse causation, time-varying confounding, selection, and the limits of longitudinal association. The article separates intervention effects from mediation and distinguishes target engagement, molecular reversibility, functional normalization, and clinical benefit. Concordant biomarker and clinical improvements do not automatically establish a fibrinogen-mediated mechanism. Laboratory endpoints are not presumed to be validated surrogates for patient outcomes, and sustained normalization after intervention withdrawal is distinguished from suppression, residual intervention activity, and interruption of autonomous feedback. Four operational tables summarize measurement domains, study designs, discordant findings, and GO/MODIFY/NO-GO decisions. Two appendices provide planning instruments for a longitudinal cohort with nested experiments and a mechanistic proof-of-concept study. No original participant data, experimental results, or clinical efficacy findings are reported. The framework requires prospective evaluation and does not establish an autonomous fibrinogen-related maintenance circuit in human disease.